Advertisement

Topics

Enbrel® (etanercept) Company Profile

01:31 EST 21st November 2017 | BioPortfolio

Enbrel® (etanercept) is a TNF inhibitor approved for the following indications: moderately to severely active rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine) and psoriasis.


News Articles [52 Associated News Articles listed on BioPortfolio]

Real world switching data for etanercept biosimilar Benepali

Real world evidence from a study of etanercept biosimilar Benepali (SB4) compared to Amgen/Pfizer’s arthritis blockbuster Enbrel (etanercept) have demonstrated ‘sustained efficacy and safety, and ...

Amgen introduces Enbrel Mini single-dose cartridges with reusable auto-injector

Amgen has announced the US launch of Enbrel Mini single-dose prefilled cartridge with AutoTouch reusable autoinjector tp provide additional administration option for Enbrel (Etanercept) users.

Prefilled Drug Cartridge Launched To Treat Arthritis, Other Chronic Conditions

NewsErgonomically designed reusable autoinjector provides an additional administration option for Enbrel (etanercept) users. The new Enbrel Mini with AutoTouch was approved by the FDA in September 201...

Monthly News Roundup - August 2016

FDA Approves Erelzi: Sandoz’s Biosimilar For Enbrel A third U.S. biosimilar has been FDA-approved; this time it’s Erelzi (etanercept-szzs), a biosimilar to Amgen’s tumor necrosis factor (TNF) b...

EC Clears Sandoz's Erelzi Biosimilar Etanercept Copy of Amgen's Enbrel

The European Commission approved Sandoz’s Erelzi® (biosimilar etanercept), a copy of Amgen’s Enbrel®, for all the reference drug’s indications, including rheumatoid arthritis, axial sp...

Novartis’ etanercept biosimilar approved in Europe to treat inflammatory diseases

The European Commission (EC) has approved Novartis’ Erelzi, the biosimilar of Amgen and Pfizer’s Enbrel (etanercept), for the treatment of multiple inflammatory diseases.

Daiichi Sankyo ends deal with Coherus for etanercept biosimilar in Japan

Daiichi Sankyo announced on 5 July 2017 that it was ending its co-development in Japan with Coherus BioSciences (Coherus) of a biosimilar to Amgen’s arthritis drug Enbrel (etanercept).

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Revision: 51, Authorised

Drugs and Medications [5 Associated Drugs and Medications listed on BioPortfolio]

Enbrel [Physicians Total Care, Inc.]

These highlights do not include all the information needed to use Enbrel safely and effectively. See full prescribing information for Enbrel.Enbrel (etanercept)Solution for Subcutaneous UseInitial U.S...

Enbrel [Immunex Corporation]

These highlights do not include all the information needed to use Enbrel safely and effectively. See full prescribing information for Enbrel. Enbrel (etanercept)Solution for Subcutaneous UseInitial U....

Kineret [Swedish Orphan Biovitrum AB (publ)]

These highlights do not include all the information needed to use Kineret safely and effectively. See full prescribing information for Kineret. Kineret® (anakinra) For injection, for subcutaneous use...

Arcalyst [Regeneron Pharmaceuticals, Inc.]

These highlights do not include all the information needed to use ARCALYST safely and effectively. See full prescribing information for ARCALYST. ARCALYST (rilonacept)Injection for Subcutaneous UseIni...

Remicade [Janssen Biotech, Inc.]

These highlights do not include all the information needed to use REMICADE safely and effectively. See full prescribing information for REMICADE.  REMICADE (infliximab) Lyophilized Concentrate for In...

PubMed Articles [36 Associated PubMed Articles listed on BioPortfolio]

Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products.

Fusion protein and monoclonal antibody-based tumor necrosis factor (TNF) inhibitors represent established treatment options for a range of inflammatory diseases. Regulatory authorities have outlined t...

Manufacturing history of etanercept (Enbrel(ࣨ)): Consistency of product quality through major process revisions.

Etanercept (ETN) (Enbrel®) is a soluble protein that binds to, and specifically inhibits, tumor necrosis factor (TNF), a proinflammatory cytokine. ETN is synthesized in Chinese hamster ovary cells by...

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.

To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA.

Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis.

Biologic therapies have revolutionized the treatment of psoriasis; however, their use is limited by costs. Ixekizumab was more effective than etanercept in the UNCOVER trials, and the Food and Drug Ad...

Retrospective Study of Patients on Etanercept Therapy for Rheumatic Diseases in Patients With Chronic Hepatitis C Virus.

Treatment of rheumatic diseases with concurrent hepatitis C virus (HCV) infection is a therapeutic challenge. Etanercept has no known hepatotoxicity; however there is a concern for worsening of HCV in...

Clinical Trials [221 Associated Clinical Trials listed on BioPortfolio]

Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children

This postmarketing surveillance study will evaluate the safety profile of Enbrel (etanercept) in an Indian population. It will provide surveillance on a currently approved indication for E...

Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes

The purpose of this study is to determine the preference of RA patients for the new Enbrel® (etanercept) pre-filled syringe in patients who are already taking Enbrel®.

Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan

The special use-results surveillance is conducted in patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted in the actual setting of use after...

Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel in Psoriasis

The purpose of this study is to evaluate the use of Enbrel® (etanercept) in the treatment of psoriasis in patients for a period of up to 1 year.

Enbrel® in Psoriatic Arthritis

This study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients. Enbrel®, also known as etanercept, has already been approved b...

Companies [3 Associated Companies listed on BioPortfolio]

Enbrel® (etanercept)

Enbrel® (etanercept) is a TNF inhibitor approved for the following indications: moderately to severely active rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthr...

ENBREL

ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheuma...

VLST Corp

VLST Corporation discovers and develops novel therapeutics for the treatment of inflammatory and autoimmune diseases. Disease areas in which the company’s technology may have utility include multip...

More Information about "Enbrel® (etanercept)" on BioPortfolio

We have published hundreds of Enbrel® (etanercept) news stories on BioPortfolio along with dozens of Enbrel® (etanercept) Clinical Trials and PubMed Articles about Enbrel® (etanercept) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Enbrel® (etanercept) Companies in our database. You can also find out about relevant Enbrel® (etanercept) Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...


Corporate Database Quicklinks



Searches Linking to this Company Record